Stoke Therapeutics, Inc. is a biotechnology company focused on restoring protein expression through RNA medicine. Utilizing its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke develops antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. The company primarily targets diseases of the central nervous system and the eye caused by haploinsufficiency, with its lead product, zorevunersen, in development for Dravet syndrome and undergoing a Phase 3 study. Stoke is headquartered in Bedford, Massachusetts.
- Website
- www.stoketherapeutics.com
- Issuer profile
- All listings